SPA
XERS icon

Sherbrooke Park Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

Sherbrooke Park Advisers’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,325
Closed -$114K – 745
2025
Q2 		$114K Buy
24,325
+9,448
+64% +$43.3K 0.05% 449
2025
Q1 		$81.7K Sell
14,877
-8,449
-36% -$34.1K 0.04% 530
2024
Q4 		$79.1K Buy
+23,326
New +$75K 0.03% 690

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Sherbrooke Park Advisers's XERS Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 24,325 shares — an estimated $114K sold.

Sherbrooke Park Advisers first reported a position in XERS in Q4 2024 and held it in 3 quarters. The position peaked at $114K in Q2 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 24,325 Xeris Biopharma Holdings shares in Q3 2025, an estimated $114K.
  • Sherbrooke Park Advisers first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Xeris Biopharma Holdings position peaked at $114K in Q2 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.